These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16136047)

  • 1. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients.
    Mu LJ; Kyte JA; Kvalheim G; Aamdal S; Dueland S; Hauser M; Hammerstad H; Waehre H; Raabe N; Gaudernack G
    Br J Cancer; 2005 Oct; 93(7):749-56. PubMed ID: 16136047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.
    Heiser A; Coleman D; Dannull J; Yancey D; Maurice MA; Lallas CD; Dahm P; Niedzwiecki D; Gilboa E; Vieweg J
    J Clin Invest; 2002 Feb; 109(3):409-17. PubMed ID: 11828001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells.
    Kyte JA; Gaudernack G
    Cancer Immunol Immunother; 2006 Nov; 55(11):1432-42. PubMed ID: 16612595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.
    Kyte JA; Mu L; Aamdal S; Kvalheim G; Dueland S; Hauser M; Gullestad HP; Ryder T; Lislerud K; Hammerstad H; Gaudernack G
    Cancer Gene Ther; 2006 Oct; 13(10):905-18. PubMed ID: 16710345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
    Fuessel S; Meye A; Schmitz M; Zastrow S; Linné C; Richter K; Löbel B; Hakenberg OW; Hoelig K; Rieber EP; Wirth MP
    Prostate; 2006 Jun; 66(8):811-21. PubMed ID: 16482569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
    Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
    BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines.
    Mu LJ; Gaudernack G; Saebøe-Larssen S; Hammerstad H; Tierens A; Kvalheim G
    Scand J Immunol; 2003 Nov; 58(5):578-86. PubMed ID: 14629630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
    Thomas-Kaskel AK; Zeiser R; Jochim R; Robbel C; Schultze-Seemann W; Waller CF; Veelken H
    Int J Cancer; 2006 Nov; 119(10):2428-34. PubMed ID: 16977630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell gene therapy.
    Onaitis M; Kalady MF; Pruitt S; Tyler DS
    Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.
    Hildenbrand B; Sauer B; Kalis O; Stoll C; Freudenberg MA; Niedermann G; Giesler JM; Jüttner E; Peters JH; Häring B; Leo R; Unger C; Azemar M
    Prostate; 2007 Apr; 67(5):500-8. PubMed ID: 17262804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA.
    Barrou B; Benoît G; Ouldkaci M; Cussenot O; Salcedo M; Agrawal S; Massicard S; Bercovici N; Ericson ML; Thiounn N
    Cancer Immunol Immunother; 2004 May; 53(5):453-60. PubMed ID: 14760510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.
    Westdorp H; Creemers JHA; van Oort IM; Schreibelt G; Gorris MAJ; Mehra N; Simons M; de Goede AL; van Rossum MM; Croockewit AJ; Figdor CG; Witjes JA; Aarntzen EHJG; Mus RDM; Brüning M; Petry K; Gotthardt M; Barentsz JO; de Vries IJM; Gerritsen WR
    J Immunother Cancer; 2019 Nov; 7(1):302. PubMed ID: 31727154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.
    Lesterhuis WJ; De Vries IJ; Schreibelt G; Schuurhuis DH; Aarntzen EH; De Boer A; Scharenborg NM; Van De Rakt M; Hesselink EJ; Figdor CG; Adema GJ; Punt CJ
    Anticancer Res; 2010 Dec; 30(12):5091-7. PubMed ID: 21187495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
    Arlen PM; Gulley JL; Parker C; Skarupa L; Pazdur M; Panicali D; Beetham P; Tsang KY; Grosenbach DW; Feldman J; Steinberg SM; Jones E; Chen C; Marte J; Schlom J; Dahut W
    Clin Cancer Res; 2006 Feb; 12(4):1260-9. PubMed ID: 16489082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.
    Su Z; Dannull J; Yang BK; Dahm P; Coleman D; Yancey D; Sichi S; Niedzwiecki D; Boczkowski D; Gilboa E; Vieweg J
    J Immunol; 2005 Mar; 174(6):3798-807. PubMed ID: 15749921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.
    Kouiavskaia DV; Berard CA; Datena E; Hussain A; Dawson N; Klyushnenkova EN; Alexander RB
    J Immunother; 2009; 32(6):655-66. PubMed ID: 19483644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells.
    Kyte JA; Kvalheim G; Lislerud K; thor Straten P; Dueland S; Aamdal S; Gaudernack G
    Cancer Immunol Immunother; 2007 May; 56(5):659-75. PubMed ID: 16947019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes.
    Suso EM; Dueland S; Rasmussen AM; Vetrhus T; Aamdal S; Kvalheim G; Gaudernack G
    Cancer Immunol Immunother; 2011 Jun; 60(6):809-18. PubMed ID: 21365467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
    Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy with mRNA-transfected dendritic cells.
    Gilboa E; Vieweg J
    Immunol Rev; 2004 Jun; 199():251-63. PubMed ID: 15233739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.